BioSpecifics Technologies (BSTC) recently announced positive top line data from a phase IIa study on Xiaflex for the potential treatment of frozen shoulder...(
read more)
Auxilium Pharmaceuticals, Inc. (AUXL) reported a third quarter loss of 27 cents per share, narrower than the Zacks Consensus Estimate of a loss of 30 cents and the year-ago...(
read more)
Hapoalim Securities is downgrading shares of Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL) to a Sell from Hold, and lowering its price target to $19 from $25 after it reported Q3 earnings.
In a note to clients, Hapoalim writes,...(
read more)